title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
abstract: BACKGROUND
  Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.
  
  
  METHODS
  In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects.
  
  
  RESULTS
  With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0.82 [95% CI 0.69-0.97], p=0.02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% CI for difference 1-12]), and median survival of 5 months (29 vs 24 months [1-11). 717 patients developed progressive disease or died. The progression-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0.76 [0.66-0.89], p=0.0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4-15]) and in median progression-free survival of 3 months (13 vs 10 months [1-5]).
  
  
  CONCLUSIONS
  Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.
authors.forename: M K B
authors.initials: MK
authors.lastname: Parmar
authors.forename: J A
authors.initials: JA
authors.lastname: Ledermann
authors.forename: N
authors.initials: N
authors.lastname: Colombo
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: J-F
authors.initials: JF
authors.lastname: Delaloye
authors.forename: G B
authors.initials: GB
authors.lastname: Kristensen
authors.forename: S
authors.initials: S
authors.lastname: Wheeler
authors.forename: A M
authors.initials: AM
authors.lastname: Swart
authors.forename: W
authors.initials: W
authors.lastname: Qian
authors.forename: V
authors.initials: V
authors.lastname: Torri
authors.forename: I
authors.initials: I
authors.lastname: Floriani
authors.forename: G
authors.initials: G
authors.lastname: Jayson
authors.forename: A
authors.initials: A
authors.lastname: Lamont
authors.forename: C
authors.initials: C
authors.lastname: Tropé
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin